Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.61 |
| ▸ | PPARA | Q07869 | 11/20 | 0.60 |
| ▸ | PPARG | P37231 | 6/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3371225 | 1.00 | PPARD (0.61) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3371057 | 0.92 | PPARD (0.57) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3371047 | 0.92 | PPARD (0.57) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3369920 | 0.90 | PPARD (0.70) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3374295 | 0.86 | PPARD (0.63) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3374304 | 0.86 | PPARD (0.63) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3373580 | 0.83 | PPARD (0.63) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL3374589 | 0.83 | PPARD (0.68) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3372244 | 0.83 | PPARD (0.67) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6456191 | 0.81 | PPARD (0.46) | PPARDPPARAPPARGFFAR1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537091-B1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-1537091-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| US-6809110-B2 | NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID | HOFFMANN-LA ROCHE INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | PPARD 79/4885PPARA 287/4885PPARG 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.